EGFR and amyotrophic lateral sclerosis: This finding gains clinical relevance from emerging evidence that EGFR inhibitors can ameliorate pathological and behavioral conditions in neurodegenerative diseases, including AD and amyotrophic lateral sclerosis (ALS).